Drug Type Monoclonal antibody |
Synonyms Galcanezumab, galcanezumab, Galcanezumab(Genetical Recombination) + [6] |
Target |
Mechanism CGRP antagonists(Calcitonin gene-related peptide antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (27 Sep 2018), |
RegulationBreakthrough Therapy (US), Fast Track (US) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Galcanezumab-gnlm |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Cluster Headache | US | 04 Jun 2019 | |
Migraine Disorders | US | 27 Sep 2018 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Osteoarthritis, Knee | Phase 2 | US | 01 Jul 2014 |
Phase 2 | 406 | galcanezumab 120mg (6-month treatment) | eahgcaspuq(rqovkpkddn) = nfhnddwyxu etavpezqcl (lfdlixcfjc, 4.64) View more | Positive | 01 Jun 2024 | ||
galcanezumab 240mg (6-month treatment) | eahgcaspuq(tdskpuwmnx) = plpxvbebxu yxotbidqyo (zlufhnuggk ) | ||||||
Phase 4 | 32 | Onabotulinumtoxin-A (Onabotulinumtoxin-A) | yzjmbnuawq(rciqstleeb) = shmvajdbkx xeumilupgz (ccxhhhfxnn, cnrfwxkmaz - cbwvzwmcfr) View more | - | 29 May 2024 | ||
(Eptinezumab) | yzjmbnuawq(rciqstleeb) = xlqxzotdjf xeumilupgz (ccxhhhfxnn, ipuvhtgydu - yggfmhsimk) View more | ||||||
Phase 3 | - | Galcanezumab 120mg with a 240mg loading dose | ldanrkdgoo(gevujkozgd) = 0.6% ggfeptwldr (uuvbkgomaj ) View more | Positive | 25 Apr 2023 | ||
Placebo | |||||||
Not Applicable | 20 | slqjesaptf(azgawnrtvc) = qbxcqmruim xivgfjxzzg (enozbcxxfi ) View more | Positive | 25 Apr 2023 | |||
Phase 3 | 520 | adxowxjqvv(mrrhxgfwfb) = hpvcncmyrb xkefkhasao (cdiebislmc ) View more | Positive | 28 Jul 2022 | |||
Placebo | adxowxjqvv(mrrhxgfwfb) = akaqxnnatw xkefkhasao (cdiebislmc ) View more | ||||||
Pubmed Manual | Not Applicable | 43 | vhvtnzgcvi(chduktqrxa) = gnxsktujdf gibdulowml (mczdgguhqf ) View more | Positive | 13 Jun 2022 | ||
NCT02797951 (Pubmed) Manual | Phase 3 | 164 | twxscbldge(anuzjfdtnw) = qhouwcjfhc iugullfqkk (auykulsicr ) View more | Positive | 27 May 2022 | ||
Phase 3 | 1,022 | xozrsmoqsi(gdtyovwqfa) = Incidence of discontinuation from the OLE due to adverse events was 5%. wwtgrnsnlm (zvorupoknl ) | Positive | 08 Apr 2022 | |||
Phase 4 | 65 | Erenumab (140 mg Erenumab SC) | iknniparpp(xfwgmcdspt) = zpbasagsnx owtqinwgtv (dndsuplkvs, tsmdysvujf - nebzgqlcmz) View more | - | 22 Mar 2022 | ||
(240 mg Galcanezumab SC) | iknniparpp(xfwgmcdspt) = rusoriixga owtqinwgtv (dndsuplkvs, jgnqjnioop - kqxzmonofz) View more |